fluorodeoxyglucose f18 has been researched along with taxane in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, Y; Fujiuchi, N; Imabayashi, E; Ishida, J; Kuji, I; Matsuda, H; Misumi, M; Moriya, T; Omata, J; Osaki, A; Saeki, T; Sakurai, T; Shigekawa, T; Takeuchi, H; Tamura, K; Tsuda, H; Ueda, S; Yamamoto, J | 1 |
| Arnould, L; Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Coudert, B; Coutant, C; Desmoulins, I; Dygai-Cochet, I; Fumoleau, P; Guiu, S; Humbert, O; Riedinger, JM; Toubeau, M | 1 |
| Ajani, JA; Bhutani, MS; Blum, MA; Charalampakis, N; Elimova, E; Etchebehere, E; Hofstetter, W; Lee, JH; Macapinlac, HA; Maru, D; Planjery, V; Rogers, JE; Shimodaira, Y; Shiozaki, H; Skinner, HD; Wadhwa, R; Wang, X; Weston, BR | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and taxane
| Article | Year |
|---|---|
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2015 |
2 other study(ies) available for fluorodeoxyglucose f18 and taxane
| Article | Year |
|---|---|
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed | 2012 |
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Female; Fluorodeoxyglucose F18; Genes, erbB-2; Humans; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2014 |